1. Home
  2. MDRR vs NEUP Comparison

MDRR vs NEUP Comparison

Compare MDRR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medalist Diversified REIT Inc.

MDRR

Medalist Diversified REIT Inc.

HOLD

Current Price

$12.20

Market Cap

18.3M

Sector

Real Estate

ML Signal

HOLD

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

20.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDRR
NEUP
Founded
2015
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
18.3M
20.6M
IPO Year
2015
2002

Fundamental Metrics

Financial Performance
Metric
MDRR
NEUP
Price
$12.20
$3.77
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
14.4K
47.1K
Earning Date
03-02-2026
05-23-2026
Dividend Yield
2.43%
N/A
EPS Growth
N/A
N/A
EPS
4.74
N/A
Revenue
$10,396,618.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.57
N/A
Revenue Growth
6.79
N/A
52 Week Low
$9.47
$3.19
52 Week High
$14.52
$21.31

Technical Indicators

Market Signals
Indicator
MDRR
NEUP
Relative Strength Index (RSI) 56.59 45.28
Support Level $12.17 $3.75
Resistance Level $14.04 $4.15
Average True Range (ATR) 0.23 0.15
MACD 0.06 -0.01
Stochastic Oscillator 68.70 9.52

Price Performance

Historical Comparison
MDRR
NEUP

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: